NuCana reports Phase Ib data for Acelarin in first-line biliary cancer

NuCana plc (NASDAQ:NCNA) reported interim data from the Phase Ib ABC-08 trial showing that Acelarin (NUC-1031) plus cisplatin as first-line treatment led to an

Read the full 248 word article

User Sign In